Efficacy and Safety of Savolitinib for MET-Altered Non-Small Cell Lung Cancer (NSCLC) In First-Line Setting: A Case Series

被引：0
|
作者：
Hua, Y. [1 ]
Xu, W. [1 ]
Shi, H. [1 ]
Zheng, X. [1 ]
Li, X. [1 ]
机构：
[1] Capital Med Univ, Beijing Tiantan Hosp, Beijing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
基金：
北京市自然科学基金;
关键词：
NSCLC; MET; savolitinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.12D.07
引用
收藏
页码：S652 / S653
页数：2
相关论文
共 50 条
  • [41] Efficacy and Safety of First-Line Pembrolizumab Monotherapy in Elderly Patients (Aged ≥ 75 years) with Non-Small Cell Lung Cancer
    Sugiyama, T.
    Imai, H.
    Wasamoto, S.
    Yamaguchi, O.
    Suzuki, K.
    Uchino, J.
    Minemura, H.
    Osaki, T.
    Ishii, T.
    Umeda, Y.
    Taniguchi, H.
    Kasai, T.
    Minato, K.
    Kaira, K.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S453 - S453
  • [42] Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer
    Hisao Imai
    Satoshi Wasamoto
    Ou Yamaguchi
    Kensuke Suzuki
    Tomohide Sugiyama
    Junji Uchino
    Hiroyuki Minemura
    Takashi Osaki
    Hisashi Ishii
    Yukihiro Umeda
    Keita Mori
    Mie Kotake
    Hiroshi Kagamu
    Nobutoshi Morozumi
    Hirokazu Taniguchi
    Takashi Kasai
    Koichi Minato
    Kyoichi Kaira
    Journal of Cancer Research and Clinical Oncology, 2020, 146 : 457 - 466
  • [43] First-Line Immunotherapy in Elderly Patients with Stage iv Non-Small Cell Lung Cancer: an Early Efficacy and Safety Assessment
    Kuon, Jonas
    Blasi, Miriam
    Grosch, Heidrun
    Christopoulos, Petros
    Wiedemann, Christiane
    Herth, Felix
    Heussel, Claus-Peter
    Stenzinger, Albrecht
    Thomas, Michael
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 118 - 119
  • [44] Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer
    Imai, Hisao
    Wasamoto, Satoshi
    Yamaguchi, Ou
    Suzuki, Kensuke
    Sugiyama, Tomohide
    Uchino, Junji
    Minemura, Hiroyuki
    Osaki, Takashi
    Ishii, Hisashi
    Umeda, Yukihiro
    Mori, Keita
    Kotake, Mie
    Kagamu, Hiroshi
    Morozumi, Nobutoshi
    Taniguchi, Hirokazu
    Kasai, Takashi
    Minato, Koichi
    Kaira, Kyoichi
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (02) : 457 - 466
  • [45] EFFICACY AND SAFETY OF FIRST LINE BEVACIZUMAB PLUS CHEMOTHERAPY IN NON SQUAMOUS NON SMALL CELL LUNG CANCER (NSCLC)
    Chatterjee, Prasenjit
    Saha, Subrata
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1294 - S1294
  • [46] Cancer cachexia as a determinant of efficacy of first-line pembrolizumab in patients with advanced non-small cell lung cancer
    Fujii, Hironori
    Araki, Ayumu
    Iihara, Hirotoshi
    Kaito, Daizo
    Hirose, Chiemi
    Kinomura, Motohiko
    Yamazaki, Mizuki
    Endo, Junki
    Inui, Toshiya
    Yanase, Komei
    Sasaki, Yuka
    Gomyo, Takenobu
    Sakai, Chizuru
    Kawae, Daisuke
    Kitamura, Yu
    Fukui, Masachika
    Kobayashi, Ryo
    Ohno, Yasushi
    Suzuki, Akio
    MOLECULAR AND CLINICAL ONCOLOGY, 2022, 16 (04)
  • [47] First-Line Therapy of Mutated Non-Small Cell Lung Cancer: An Update
    Stoehlmacher-Williams, Jan
    ONKOLOGIE, 2012, 35 (05): : 293 - 299
  • [48] First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly
    Losanno, Tania
    Gridelli, Cesare
    CURRENT ONCOLOGY REPORTS, 2021, 23 (10)
  • [49] Bevacizumab as first-line treatment for advanced non-small cell lung cancer
    Socinski, Mark A.
    DRUGS OF TODAY, 2008, 44 (04) : 293 - 301
  • [50] The use of pemetrexed for the first-line treatment of non-small cell lung cancer
    Silva, S.
    Colquitt, J.
    Hatton, M. Q.
    Mohanamurali, J.
    Lee, C.
    Danson, S.
    Fisher, P.
    Woll, P.
    LUNG CANCER, 2014, 83 : S13 - S13
12345